An endothelin-converting enzyme mediates the conversion from low-potency pro-endothelin to potent endothelin-1 (ET-1). Increased ET-1 levels have been observed in pulmonary hypertension of various etiologies in infants. We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). Twenty-two unanesthetized, chronically instrumented newborn piglets received a continuous infusion of GBS (3.5 ϫ 10 8 colony-forming units/kg/min) while exposed to 100% O 2 . They were randomly assigned to receive a placebo (PL) or an ECEI (phosphoramidon, 30 mg/kg i.v.) 15 min after sustained pulmonary hypertension. Comparison of hemodynamic measurements and arterial blood gases at baseline and over the first 210 min from the onset of pulmonary hypertension was performed between groups. GBS infusion caused significant increases in mean pulmonary artery pressure, pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and PVR/SVR, and significant decreases in cardiac output, pH, and base excess. After the administration of ECEI, a significant reduction in pulmonary artery pressure (p Ͻ 0.0001), PVR (p Ͻ 0.001), and PVR/SVR (p Ͻ 0.01) and an improvement in cardiac output (p Ͻ 0.01) were observed during GBS infusion. The decrease in pH (p Ͻ 0.001) and base excess (p Ͻ 0.001) during GBS infusion was less marked after the administration of ECEI compared with the PL. Plasma ET-1 levels were obtained in 20 additional piglets; levels were significantly lower in the ECEI compared with PL after 3 h of GBS infusion (p Ͻ 0.02). All animals in the ECEI group survived the study period as opposed to 25% survival in the PL group (p Ͻ 0.001). These data suggest that the increased circulating ET-1 levels mediate, in part, the GBSinduced pulmonary hypertension. Abbreviations BE, base excess ECE, endothelin-converting enzyme ECEI, endothelin-converting enzyme inhibitor ET-1, endothelin-1 GBS, group B Streptococcus PL, placebo Ppa, pulmonary artery pressure Psa, systemic pressure Pra, right atrial pressure Pwp, pulmonary wedge pressure CO, cardiac output PVR, pulmonary vascular resistance SVR, systemic vascular resistance ABG, arterial blood gas CPB, cardiopulmonary bypass Persistent pulmonary hypertension of the newborn is a clinical syndrome that can occur idiopathically or in association with diverse neonatal cardiorespiratory disorders, such as asphyxia, meconium aspiration, sepsis, pneumonia, acute respiratory distress syndrome, and lung hypoplasia (1). Although striking differences exist among these conditions, they can share common pathophysiologic features, including high pulmonary vascular resistance leading to extrapulmonary right-toleft shunting of blood across the ductus arteriosus or foramen ovale and hypoxemia (2). The incidence is 1.9 in every 1,000 live births (1, 2) and it causes significant morbidity and mortality.The mechanisms that cause severe pulmonary hypertens...